ICU Medical sold almost the same amount of product and kept much more of the revenue. That is the cleanest reading of its latest three months, until the source of the margin lift comes into view.
Revenue rose just 0.5% from the comparable period a year earlier, but gross profit increased 13% and operating income nearly quadrupled to $39.1 million. The company’s gross margin expanded by 4.7 percentage points. Net income went the other way, falling 46% to $19.1 million, and diluted EPS declined 47% to $0.76.
The biggest piece of the operating improvement was not a new product or a sudden burst of demand. ICU Medical received $18.9 million in tariff refunds during the second quarter, which management says added 3.4 percentage points to gross margin. The company also pointed to its sale of a 60% interest in the lower-margin IV Solutions business in May 2025, a portfolio change that lifted the comparison.
Management put the tariff refund and the divestiture directly into its margin explanation:
"The increase in gross margin for the three months ended June 30, 2026, as compared to the same period in the prior year, was primarily driven by (i) 18.9 million or 3.4% impact from tariff refunds that were received during the second quarter of 2026 and (ii) approximately a 1.7% impact from the May 1, 2025 sale of a 60% interest in our lower margin IV Solutions business."
10-Q 2026-08-06; margin
That leaves a simple tension: the operating line improved sharply, but the filing’s clearest margin receipts are not recurring sales growth. ICU Medical does not identify a single reason for the decline in net income in the disclosed discussion.
There was genuine volume growth inside the flat consolidated number. Infusion Systems revenue rose 12.7%, with the company attributing about $26 million of the increase to higher sales volumes of large-volume pump hardware. Smaller product lines were weaker, including Pain Management and Temperature Management.
The company’s wording is specific about what moved the largest business line:
"Infusion Systems revenue increased for the three and six months ended June 30, 2026, as compared to the same periods in the prior year, primarily driven by approximately $26 million and $33 million, respectively, in increased sales volumes of LVP hardware."
10-Q 2026-08-06; revenue
The balance-sheet signals were less dramatic. Inventory fell 1.5%, which ICU Medical attributed to strong sales volume for certain products and delays in production during plant transfers. Accounts receivable rose 2.2%. Capital-spending intensity declined, while free-cash-flow margin improved by 5.8 percentage points, giving the period a better cash-conversion profile even as reported earnings split in two directions.
That split fits the company’s recent operating history. ICU Medical’s 2025 revenue fell 6.3%, while its operating margin was 1.9%, so the latest 7.1% operating margin marks a large step up from a thin base. But the latest period also shows why the quality of that step matters: the top line barely grew, and a refund supplied a meaningful share of the gross-margin expansion.
ICU Medical shares closed at $166.59 on August 5, down 3.1% for the day. Its next report will provide the factual comparison for gross margin with the tariff refund separated from ordinary operations.
The unresolved point is plain: ICU Medical produced far more operating profit, but the period’s strongest margin help came from outside the sales engine.
Source: ICU Medical 10-Q filed August 6, 2026.